查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026749

肝病診斷市場預測至2034年—按疾病類型、診斷方法、最終用戶和地區分類的全球分析

Liver Disease Diagnostics Market Forecasts to 2034 - Global Analysis By Disease Type (Viral Hepatitis, Alcoholic Liver Disease, Non-alcoholic Fatty Liver Disease, Liver Cancer and Other Disease Types), Technique, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球肝病診斷市場規模將達到 509 億美元，並在預測期內以 8.1% 的複合年成長率成長，到 2034 年將達到 950 億美元。

肝臟疾病的診斷對於識別和治療多種肝臟相關疾病至關重要。這些診斷方法包括各種檢查和影像技術，旨在評估肝臟健康狀況、識別異常情況並確定肝臟疾病的根本原因。此外，測量肝臟酵素水平（例如丙氨酸胺基轉移酶(ALT) 和天冬氨酸胺基轉移酶(AST)）的血液檢查，以及評估特定抗體和病毒標記存在的檢測也是常用的診斷工具。

根據世界衛生組織 (WHO) 2022 年 6 月發布的報告，全球估計有 5,800 萬人患有慢性C型肝炎病毒感染，每年報告的新病例約有 150 萬例。

提高公眾意識和篩檢力度

非營利組織和醫療機構所進行的宣傳活動提高了公眾對肝病嚴重性的認知，從而增加了對肝病診斷的需求。此外，針對高風險族群（例如有藥物濫用史者或易患篩檢的特定族群）的主動篩檢計畫也提高了早期診斷率。這不僅減輕了醫療系統的負擔，而且人們對預防醫學日益成長的興趣和認知，也使人們能夠透過定期篩檢來管理自身的肝臟健康。

高級診斷費用高昂

肝病尖端診斷技術（包括先進影像學和分子檢測）成本高昂是一大障礙。總成本取決於高昂的初始投資、持續的維護費用以及專業培訓的需求。此外，這種經濟障礙也阻礙了這些診斷方法在患者和醫療機構中的廣泛應用和普及。

個人化醫療的進展

隨著個人化醫療的發展，肝病診斷市場湧現出巨大的機會。透過根據個體的基因組成、生活方式以及疾病的具體特徵來客製化診斷策略，可以更精準地診斷和治療肝病。此外，基因組學和分子譜分析的進步也推動了標靶診斷工具的開發，為更有效率、更個人化的患者照護鋪平了道路。

合規和監管挑戰

肝病診斷市場正受到日益嚴格且不斷變化的法規環境的威脅。企業在時間和資源方面面臨挑戰，產品上市也可能因此延誤，因為它們需要遵守合規要求、獲得必要的核准並應對複雜的監管流程。然而，對於參與企業，違規會帶來嚴重的風險，包括法律糾紛、市場退出或受到限制。

新冠疫情的影響：

新冠疫情對肝病診斷市場造成了顯著影響。疫情引發的全球性混亂，包括封鎖、醫療系統超負荷運轉以及資源被轉移用於對抗疫情，導致擇期手術和常規就診量暫時下降，進而影響了對診斷服務的整體需求。此外，研發專案延誤、供應鏈中斷以及醫療優先事項的調整也為市場參與企業帶來了挑戰。另一方面，疫情加速了遠端醫療和遠距監測解決方案的普及，凸顯了強大診斷能力的重要性。

在預測期內，非酒精性脂肪肝（NAFLD）細分市場預計將成為最大的細分市場。

非酒精性脂肪肝病 (NAFLD) 預計將佔據最大市場佔有率。隨著肥胖和METABOLIC INC.症候群的日益普遍，NAFLD 正逐漸成為全球慢性肝病的主要原因之一。此外，NAFLD 的盛行率不斷上升，從輕度脂肪肝到更嚴重的疾病，例如非酒精性脂肪性肝炎 (NASH)，都推動了該細分市場的主導地位。因此，對先進影像技術和血液檢測的需求顯著增加，以便準確診斷和分期 NAFLD。

在預測期內，研究機構板塊預計將呈現最高的複合年成長率。

預計在預測期內複合年成長率最高的細分市場是研究機構。研究機構在推動診斷設備和流程的創新和技術進步方面發揮著至關重要的作用。該細分市場的強勁成長歸功於人們對轉化研究、生物標記發現和創新診斷技術開發日益成長的興趣。此外，研究機構開展臨床試驗、檢驗診斷方法，並與診斷設備製造商和醫療保健機構合作，主導新診斷技術的開發。不斷成長的研究活動以及政府津貼和資助正在推動研究機構產業的發展。

市佔率最大的地區：

預計北美將佔據最大的市場佔有率。該地區之所以能保持領先地位，部分原因在於其健全的法規環境鼓勵創新、高額的醫療費用支出、技術進步以及完善的醫療保健基礎設施。此外，北美在肝病診斷市場也佔據主導地位，這部分歸功於該地區擁有眾多主要市場參與者和研究機構，以及積極採用先進診斷技術的態度。

複合年成長率最高的地區：

預計亞太地區的醫療診斷市場將以最高的複合年成長率成長。人口成長、慢性病患病率上升、公眾對疾病早期檢測意識的提高以及對醫療基礎設施的大量投資都是推動這一成長的因素。這一快速成長主要得益於中產階級的壯大、政府為改善醫療服務可及性所做的努力以及中國和印度等國的技術進步。此外，亞太地區充滿活力，並重視採用尖端診斷解決方案，因此該地區在醫療診斷行業擁有強勁成長的有利條件。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球肝病診斷市場：依疾病類型分類

  • 病毒性肝炎
  • 酒精性肝臟疾病
  • 非酒精性脂肪肝（NAFLD）
  • 肝癌
  • 其他疾病類型

第6章 全球肝病診斷市場：依診斷方法分類

  • 內視鏡檢查
  • 切片檢查
  • 醫學影像技術
    • 超音波
    • MRI
    • 電腦斷層掃描
  • 臨床檢測
    • 驗血
    • 肝功能檢查
    • 基因檢測
  • 其他方法

第7章 全球肝病診斷市場：依最終用戶分類

  • 醫院
  • 實驗室
  • 研究機構
  • 其他最終用戶

第8章 全球肝病診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Abbott Laboratories
  • Horiba Medical
  • F. Hoffmann-La Roche Ltd.
  • Cosara Diagnostics Pvt Ltd
  • Laboratory Corporation of America Holdings
  • Bio-Rad Laboratories Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Fujifilm Corporation
  • PerkinElmer
  • Biosino Bio-Technology and Science Inc
  • Quest Diagnostics Incorporated
  • Trivitron Healthcare
  • Boston Scientific Corporation
  • Qiagen NV
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc
  • Randox Laboratories Ltd.
Product Code: SMRC24751

According to Stratistics MRC, the Global Liver Disease Diagnostics Market is accounted for $50.9 billion in 2026 and is expected to reach $95.0 billion by 2034 growing at a CAGR of 8.1% during the forecast period. Diagnostics for liver diseases are essential for determining and treating a wide range of liver-related conditions. These diagnostics include a variety of procedures and imaging methods designed to evaluate the liver's health, identify anomalies, and identify the underlying causes of liver diseases. Moreover, blood tests to measure liver enzyme levels, such as alanine transaminase (ALT) and aspartate transaminase (AST), as well as tests to assess the presence of particular antibodies or viral markers, are commonly used diagnostic tools.

According to report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.

Market Dynamics:

Driver:

Growing consciousness and screening initiatives

Liver disease diagnostics are in high demand due to growing public awareness of the seriousness of liver diseases, which has been fueled by campaigns from non-profits and healthcare groups. Additionally, early-stage diagnoses are increasing as a result of proactive screening programs, which typically target high-risk populations such as those with a history of substance abuse or particular demographics predisposed to liver disorders. In addition to lessening the strain on healthcare systems, this increased focus and awareness of preventive healthcare also give people the power to take control of their liver health through routine screenings.

Restraint:

Exorbitant expense of advanced diagnosis

A major barrier is the expense of cutting-edge liver disease diagnostics, which include sophisticated imaging methods and molecular testing. The total cost is influenced by a high initial investment, ongoing maintenance expenses, and the requirement for specialized training. Furthermore, this financial obstacle prevents these diagnostics from being widely used and made accessible to patients and healthcare organizations alike.

Opportunity:

Developments in customized medicine

There is a large opportunity for the liver disease diagnostics market due to the changing face of personalized medicine. Liver disease diagnosis and treatment can be made more accurate by customizing diagnostic strategies based on a person's genetic composition, lifestyle choices, and unique disease features. Moreover, the creation of targeted diagnostic tools is made possible by developments in genomics and molecular profiling, which open the door to more efficient and customized patient care.

Threat:

Issues with compliance and regulatory difficulties

The market for liver disease diagnostics is threatened by stricter and more dynamic regulatory environments. Companies face difficulties in terms of time, resources, and possible delays in product launches when they must follow compliance requirements, secure required approvals, and navigate complex regulatory processes. However, for market participants, non-compliance poses a serious risk of legal problems, market withdrawals, or restrictions.

Covid-19 Impact:

The market for liver disease diagnostics has been significantly impacted by the COVID-19 pandemic. The pandemic's worldwide disruption, which included lockdowns, overburdened healthcare systems, and the redirection of resources to fight the virus, temporarily, reduced the number of elective surgeries and routine medical visits, which had an impact on the demand for diagnostic services as a whole. Additionally, market participants faced difficulties due to delays in R&D projects, interruptions in the supply chain, and changes in healthcare priorities. Positively, the pandemic accelerated the adoption of tele-health and remote monitoring solutions by highlighting the significance of strong diagnostic capabilities.

The Non-alcoholic Fatty Liver Disease (NAFLD) segment is expected to be the largest during the forecast period

The non-alcoholic fatty liver disease (NAFLD) segment is anticipated to hold the largest share. Since obesity and metabolic syndrome are becoming more common, non-alcoholic fatty liver disease (NAFLD) has emerged as a major global cause of chronic liver disease. Furthermore, the rising prevalence of NAFLD, which can vary from mild hepatic steatosis to more serious illnesses like non-alcoholic steatohepatitis (NASH), is what drives the segment's dominance. Because of this, there has been a noticeable increase in the need for liver disease diagnostics, such as cutting-edge imaging methods and blood tests for precise NAFLD diagnosis and staging.

The Research Institutes segment is expected to have the highest CAGR during the forecast period

The segment with the highest CAGR during the estimation period is research institutes. Research institutes are essential for fostering innovation and technical progress in the development of diagnostic instruments and procedures. The robust growth of this segment can be attributed to the growing emphasis on translational research, biomarker discovery, and the development of innovative diagnostic technologies. Moreover, research institutes conduct clinical studies, validate diagnostic assays, and lead the way in developing novel diagnostic techniques in partnership with diagnostic companies and healthcare providers. Government grants and funding, along with the increased volume of research activity, are driving the Research Institutes sector forward.

Region with largest share:

North America is expected to hold the largest market share. A strong regulatory environment that encourages innovation, high healthcare spending, technological advancements, and a well-established healthcare infrastructure are some of the reasons for the region's dominance. Additionally, North America holds a dominant position in the liver disease diagnostics market due in part to the existence of important market players, research institutions, and a proactive approach towards adopting advanced diagnostic technologies.

Region with highest CAGR:

The healthcare diagnostics market is expected to grow at the highest CAGR in the Asia-Pacific region. The region's expanding population, the rising frequency of chronic diseases, the increased public awareness of early disease detection, and the significant investments made in healthcare infrastructure are all contributing factors to this. The rapid growth is mostly being driven by middle-class population expansion, government initiatives to increase healthcare accessibility, and technological advancements in countries like China and India. Furthermore, the Asia-Pacific region is well-positioned for strong growth in the healthcare diagnostics industry due to its dynamic nature and emphasis on implementing cutting-edge diagnostic solutions.

Key players in the market

Some of the key players in Liver Disease Diagnostics market include Abbott Laboratories, Horiba Medical, F. Hoffmann-La Roche Ltd., Cosara Diagnostics Pvt Ltd, Laboratory Corporation of America Holdings, Bio-Rad Laboratories Inc., Meril Life Sciences Pvt. Ltd., Fujifilm Corporation, PerkinElmer, Biosino Bio-Technology and Science Inc, Quest Diagnostics Incorporated, Trivitron Healthcare, Boston Scientific Corporation, Qiagen N.V, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc and Randox Laboratories Ltd.

Key Developments:

In December 2023, F. Hoffmann-La Roche Ltd. announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In August 2022, HORIBA, one of the global leaders in a wide range of medical diagnostic equipment, and SigTuple, a medtech company that develops AI-powered digital microscopy solutions, announced today a partnership to accelerate adoption of SigTuple's AI100 across the Indian subcontinent. HORIBA, a medical diagnostic company, and SigTuple, a MedTech company, on Monday, announced a partnership to accelerate the adoption of SigTuple's AI100 across the Indian subcontinent.

Disease Types Covered:

  • Viral Hepatitis
  • Alcoholic Liver Disease
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Liver Cancer
  • Other Disease Types

Techniques Covered:

  • Endoscopy
  • Biopsy
  • Imaging Techniques
  • Laboratory Tests
  • Other Techniques

End Users Covered:

  • Hospitals
  • Laboratories
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liver Disease Diagnostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Viral Hepatitis
  • 5.3 Alcoholic Liver Disease
  • 5.4 Non-alcoholic Fatty Liver Disease (NAFLD)
  • 5.5 Liver Cancer
  • 5.6 Other Disease Types

6 Global Liver Disease Diagnostics Market, By Technique

  • 6.1 Introduction
  • 6.2 Endoscopy
  • 6.3 Biopsy
  • 6.4 Imaging Techniques
    • 6.4.1 Ultrasound
    • 6.4.2 MRI
    • 6.4.3 CT Scan
  • 6.5 Laboratory Tests
    • 6.5.1 Blood Tests
    • 6.5.2 Liver Function Tests
    • 6.5.3 Genetic Tests
  • 6.6 Other Techniques

7 Global Liver Disease Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Laboratories
  • 7.4 Research Institutes
  • 7.5 Other End Users

8 Global Liver Disease Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Horiba Medical
  • 10.3 F. Hoffmann-La Roche Ltd.
  • 10.4 Cosara Diagnostics Pvt Ltd
  • 10.5 Laboratory Corporation of America Holdings
  • 10.6 Bio-Rad Laboratories Inc.
  • 10.7 Meril Life Sciences Pvt. Ltd.
  • 10.8 Fujifilm Corporation
  • 10.9 PerkinElmer
  • 10.10 Biosino Bio-Technology and Science Inc
  • 10.11 Quest Diagnostics Incorporated
  • 10.12 Trivitron Healthcare
  • 10.13 Boston Scientific Corporation
  • 10.14 Qiagen N.V
  • 10.15 Siemens Healthcare GmbH
  • 10.16 Thermo Fisher Scientific Inc
  • 10.17 Randox Laboratories Ltd.

List of Tables

  • Table 1 Global Liver Disease Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 3 Global Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 4 Global Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 5 Global Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 6 Global Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 7 Global Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 8 Global Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 9 Global Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 10 Global Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 11 Global Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 12 Global Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 13 Global Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 14 Global Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 15 Global Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 16 Global Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 17 Global Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 18 Global Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 19 Global Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 20 Global Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 22 Global Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 23 Global Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 24 Global Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 25 North America Liver Disease Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 26 North America Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 27 North America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 28 North America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 29 North America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 30 North America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 31 North America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 32 North America Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 33 North America Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 34 North America Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 35 North America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 36 North America Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 37 North America Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 38 North America Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 39 North America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 40 North America Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 41 North America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 42 North America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 43 North America Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 44 North America Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 45 North America Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 46 North America Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 47 North America Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 48 North America Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 49 Europe Liver Disease Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 50 Europe Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 51 Europe Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 52 Europe Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 53 Europe Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 54 Europe Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 55 Europe Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 56 Europe Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 57 Europe Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 58 Europe Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 59 Europe Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 60 Europe Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 61 Europe Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 62 Europe Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 63 Europe Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 64 Europe Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 65 Europe Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 66 Europe Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 67 Europe Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 68 Europe Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 69 Europe Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 70 Europe Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 71 Europe Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 72 Europe Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 73 Asia Pacific Liver Disease Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 74 Asia Pacific Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 75 Asia Pacific Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 76 Asia Pacific Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 77 Asia Pacific Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 78 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 79 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 80 Asia Pacific Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 81 Asia Pacific Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 82 Asia Pacific Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 83 Asia Pacific Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 84 Asia Pacific Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 85 Asia Pacific Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 86 Asia Pacific Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 87 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 88 Asia Pacific Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 89 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 90 Asia Pacific Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 91 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 92 Asia Pacific Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 93 Asia Pacific Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 94 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 95 Asia Pacific Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 96 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 97 South America Liver Disease Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 98 South America Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 99 South America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 100 South America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 101 South America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 102 South America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 103 South America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 104 South America Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 105 South America Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 106 South America Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 107 South America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 108 South America Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 109 South America Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 110 South America Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 111 South America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 112 South America Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 113 South America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 114 South America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 115 South America Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 116 South America Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 117 South America Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 118 South America Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 119 South America Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 120 South America Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 121 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 122 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 123 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2023-2034) ($MN)
  • Table 124 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2023-2034) ($MN)
  • Table 125 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2023-2034) ($MN)
  • Table 126 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 127 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 128 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Technique (2023-2034) ($MN)
  • Table 129 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Endoscopy (2023-2034) ($MN)
  • Table 130 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 131 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2023-2034) ($MN)
  • Table 132 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 133 Middle East & Africa Liver Disease Diagnostics Market Outlook, By MRI (2023-2034) ($MN)
  • Table 134 Middle East & Africa Liver Disease Diagnostics Market Outlook, By CT Scan (2023-2034) ($MN)
  • Table 135 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 136 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 137 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2023-2034) ($MN)
  • Table 138 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Genetic Tests (2023-2034) ($MN)
  • Table 139 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Techniques (2023-2034) ($MN)
  • Table 140 Middle East & Africa Liver Disease Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 141 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 142 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 143 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 144 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)